Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Effect of fenofibrate therapy on paraoxonase1 status in patients with low HDL-C levels.

Atherosclerosis - 1 Jan 2008

Phuntuwate Wimon, Suthisisang Chuthamanee, Koanantakul Banhan, Chaloeiphap Preecha, Mackness Bharti, Mackness Mike

Abstract excerpt

OBJECTIVES: We evaluated the effect of micro-coated fenofibrate on lipid parameters, high sensitivity C-reactive protein and paraoxonase1 levels in dyslipidemic patients with low high-density lipoproteins levels. In addition, the effects of the paraoxonase1 polymorphisms on lipid and paraoxonase1 responses to fenofibrate therapy were examined. METHODS: A total of 61 dyslipidemic patients with low high-density...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aryldialkylphosphatase
Share to Cholesterol, HDL

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Gene Frequency

Share to Genotype

Share to Hyperlipidemias

Share to Hypolipidemic Agents

Share to Polymorphism, Single Nucleotide

Source

Identifiers

PMID: 17412348
DOI: 10.1016/j.atherosclerosis.2007.03.001

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Effect of fenofibrate therapy on paraoxonase1 status in patients with low HDL-C levels.PMID 17412348Read ↗

The effect of micronised fenofibrate on paraoxonase activity in patients with coronary heart disease.Semantic proximity Read ↗

Effects of fenofibrate on plasma oxidized LDL and 8-isoprostane in a sub-cohort of GOLDN participants.Semantic proximity Read ↗

Overview of fenofibrate.Semantic proximity Read ↗

The effect of CYP7A1 polymorphisms on lipid responses to fenofibrate.Semantic proximity Read ↗

Effect of fenofibrate therapy and ABCA1 polymorphisms on high-density lipoprotein subclasses in the Genetics of Lipid Lowering Drugs and Diet Network.Semantic proximity Read ↗

Effect of apolipoprotein E, peroxisome proliferator-activated receptor alpha and lipoprotein lipase gene mutations on the ability of fenofibrate to improve lipid profiles and reach clinical guideline targets among hypertriglyceridemic patients.Semantic proximity Read ↗

Pharmacological Interactions of Paraoxonase 1 (PON1): A HDL-Bound Antiatherogenic Enzyme.Semantic proximity Read ↗

Small Interfering RNA to Reduce Lipoprotein(a) in Cardiovascular DiseaseSemantic proximity Read ↗

Pharmacogenetic association of the APOA1/C3/A4/A5 gene cluster and lipid responses to fenofibrate: the genetics of lipid-lowering drugs and diet network study.Semantic proximity Read ↗

Genome-wide association study indicates variants associated with insulin signaling and inflammation mediate lipoprotein responses to fenofibrate.Semantic proximity Read ↗

[Effect of polymorphism of human intestinal fatty acid binding protein gene on the therapeutic efficacy of fenofibrate].Semantic proximity Read ↗

Balancing Low-density Lipoprotein Cholesterol Reduction and Hepatotoxicity With Lomitapide Mesylate and Mipomersen in Patients With Homozygous Familial Hypercholesterolemia.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.